Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (original) (raw)

• Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nature Rev. Cancer 2, 795–803 (2002).
  Article CAS Google Scholar
• Ide, A. G., Baker, N. H. & Warren, S. L. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol. 42, 891–899 (1939).
  Google Scholar
• Algire, G. H., Chalkley, H. W., Legallais, F. Y. & Park, H. D. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl Cancer Inst. 6, 73–85 (1945).
  Article Google Scholar
• Greenblatt, M. & Shubick, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl Cancer Inst. 41, 111–124 (1968).
  CAS PubMed Google Scholar
• Ehrmann, R. L. & Knoth, M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J. Natl. Cancer Inst. 41, 1329–1341 (1968).
  CAS PubMed Google Scholar
• Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
  Article CAS PubMed Google Scholar
• Folkman, J., Merler, E., Abernathy, C. & Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133, 275–288 (1971).
  Article CAS PubMed PubMed Central Google Scholar
• Gullino, P. M. Angiogenesis and oncogenesis. J. Natl Cancer Inst. 61, 639–643 (1978).
  CAS PubMed Google Scholar
• Folkman, J. & Klagsbrun, M. Angiogenic factors. Science 235, 442–447 (1987).
  Article CAS PubMed Google Scholar
• Klagsbrun, M. & D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol. 53, 217–239 (1991).
  Article CAS PubMed Google Scholar
• Gospodarowicz, D., Ferrara, N., Schweigerer, L. & Neufeld, G. Structural characterization and biological functions of fibroblast growth factor. Endocrin. Rev. 8, 95–114 (1987).
  Article CAS Google Scholar
• Matsuzaki, K., Yoshitake, Y., Matuo, Y., Sasaki, H. & Nishikawa, K. Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc. Natl Acad. Sci. USA 86, 9911–9915 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Dennis, P. A. & Rifkin, D. B. Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth. J. Cell. Physiol. 144, 84–98 (1990).
  Article CAS PubMed Google Scholar
• Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M. G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl Acad. Sci. USA 88, 9267–9271 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Olofsson, B. et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl Acad. Sci. USA 93, 2576–2581 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR–2) receptor tyrosine kinases. EMBO J. 15, 1751 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Orlandini, M., Marconcini, L., Ferruzzi, R. & Oliviero, S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl Acad. Sci. USA 93, 11675–11680 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Jain, R. K. Molecular regulation of vessel maturation. Nature Med. 9, 685–693 (2003).
  Article CAS PubMed Google Scholar
• Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003).
  Article CAS PubMed Google Scholar
• Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E. & Alitalo, K. Lymphangiogenesis and cancer metastasis. Nature Rev. Cancer 2, 573–583 (2002).
  Article CAS Google Scholar
• Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1983).
  Article CAS PubMed Google Scholar
• Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851–858 (1989).
  Article CAS PubMed Google Scholar
• Connolly, D. T. et al. Human vascular permeability factor. Isolation from U937 cells. J. Biol. Chem. 264, 20017–20024 (1989).
  Article CAS PubMed Google Scholar
• Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309 (1989).
  Article CAS PubMed Google Scholar
• Keck, P. J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309–1312 (1989).
  Article CAS PubMed Google Scholar
• Houck, K. A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806–1814 (1991).
  Article CAS PubMed Google Scholar
• Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947–11954 (1991).
  Article CAS PubMed Google Scholar
• Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031–26037 (1992).
  Article CAS PubMed Google Scholar
• Park, J. E., Keller, G. -A. & Ferrara, N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317–1326 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Ruhrberg, C. et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16, 2684–2698 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocrin. Rev. (in the press).
• Keyt, B. A. et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271, 7788–7795 (1996).
  Article CAS PubMed Google Scholar
• Pepper, M. S. Extracellular proteolysis and angiogenesis. Thromb. Haemost. 86, 346–355 (2001).
  Article CAS PubMed Google Scholar
• Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000).
  Article CAS PubMed Google Scholar
• Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocrin. Rev. 18, 4–25 (1997).
  Article CAS Google Scholar
• Plouet, J., Schilling, J. & Gospodarowicz, D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J. 8, 3801–3808 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368–4380 (2002).
  Article CAS PubMed Google Scholar
• Melder, R. J. et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Med. 2, 992–997 (1996).
  Article CAS PubMed Google Scholar
• Gerber, H. P. et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30366–30343 (1998).
  Article Google Scholar
• Gerber, H. P., Dixit, V. & Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273, 13313–13316 (1998).
  Article CAS PubMed Google Scholar
• Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765–14770 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Benjamin, L. E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159–165 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Carmeliet, P. Blood vessels and nerves: common signals, pathways and diseases. Nature Rev. Genet. 4, 710–720 (2003).
  Article CAS PubMed Google Scholar
• Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 5, 519–524 (1990).
  CAS PubMed Google Scholar
• de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989–991 (1992).
  Article CAS PubMed Google Scholar
• Terman, B. I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579–1586 (1992).
  Article CAS PubMed Google Scholar
• Millauer, B. et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835–846 (1993).
  Article CAS PubMed Google Scholar
• Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N. & Williams, L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl Acad. Sci. USA 90, 7533–7537 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70 (1995).
  Article CAS PubMed Google Scholar
• Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62–66 (1995).
  Article CAS PubMed Google Scholar
• Park, J. E., Chen, H. H., Winer, J., Houck, K. A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646–25654 (1994).
  Article CAS PubMed Google Scholar
• Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature Med. 8, 841–849 (2002).
  Article CAS PubMed Google Scholar
• Gerber, H. -P. et al. Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954–958 (2002).
  Article CAS PubMed Google Scholar
• Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336–3343 (1996).
  Article CAS PubMed Google Scholar
• Luttun, A. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med. 8, 831–840 (2002).
  Article CAS PubMed Google Scholar
• Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289–300 (2002).
  Article CAS PubMed Google Scholar
• LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890–893 (2003).
  Article CAS PubMed Google Scholar
• Autiero, M., Luttun, A., Tjwa, M. & Carmeliet, P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J. Thromb. Haemost. 1, 1356–1370 (2003).
  Article CAS PubMed Google Scholar
• Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735–745 (1998).
  Article CAS PubMed Google Scholar
• Safran, M. & Kaelin, W. J. Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111, 779–783 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Semenza, G. L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 54, 17–28 (2003).
  Article CAS PubMed Google Scholar
• Mole, D. R., Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J. Regulation of HIF by the von Hippel–Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 52, 43–47 (2001).
  Article CAS PubMed Google Scholar
• Lonser, R. R. et al. von Hippel–Lindau disease. Lancet 361, 2059–2067 (2003).
  Article CAS PubMed Google Scholar
• Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. Jr. & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595–10599 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
  Article CAS PubMed Google Scholar
• Jaakkola, P. et al. Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).
  Article CAS PubMed Google Scholar
• Ivan, M. et al. HIF-α targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001).
  Article CAS PubMed Google Scholar
• Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med. 9, 677–684 (2003).
  Article CAS PubMed Google Scholar
• Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B. & Marme, D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270, 25915–25919 (1995).
  Article CAS PubMed Google Scholar
• Okada, F. et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras upregulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl Acad. Sci. USA. 95, 3609–3614 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Shi, Y. -P. & Ferrara, N. Oncogenic ras fails to restore an in vivo oncogenic phenotype in embryonic stem cells lacking VEGF. Biochem. Biophys. Res. Commun. 254, 480–483 (1999).
  Article CAS PubMed Google Scholar
• Zhang, X., Gaspard, J. P. & Chung, D. C. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 61, 6050–6054 (2001).
  CAS PubMed Google Scholar
• Seno, H. et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62, 506–511 (2002).
  CAS PubMed Google Scholar
• Williams, C. S., Tsujii, M., Reese, J., Dey, S. K. & DuBois, R. N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105, 1589–1594 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Sonoshita, M. et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nature Med. 7, 1048–1051 (2001).
  Article CAS PubMed Google Scholar
• Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439–442 (1996).
  Article CAS PubMed Google Scholar
• Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435–439 (1996).
  Article CAS PubMed Google Scholar
• Gerber, H. P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149–1159 (1999).
  Article CAS PubMed Google Scholar
• Eremina, V. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707–716 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Gerber, H. P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med. 5, 623–628 (1999).
  Article CAS PubMed Google Scholar
• Ryan, A. M. et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol. 27, 78–86 (1999).
  Article CAS PubMed Google Scholar
• Bassett, D. L. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am. J. Anat. 73, 251–278 (1943).
  Article Google Scholar
• Phillips, H. S., Hains, J., Leung, D. W. & Ferrara, N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127, 965–967 (1990).
  Article CAS PubMed Google Scholar
• Ravindranath, N., Little-Ihrig, L., Phillips, H. S., Ferrara, N. & Zeleznik, A. J. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 131, 254–260 (1992).
  Article CAS PubMed Google Scholar
• Zimmermann, R. C. et al. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J. Clin. Endocrinol. Metab. 86, 768–772 (2001).
  CAS PubMed Google Scholar
• Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med. 4, 336–340 (1998).
  Article CAS PubMed Google Scholar
• Fraser, H. M. et al. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141, 995–1000 (2000).
  Article CAS PubMed Google Scholar
• Hazzard, T. M., Xu, F. & Stouffer, R. L. Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys. Biol. Reprod. 67, 1305–1312 (2002).
  Article CAS PubMed Google Scholar
• Volm, M., Koomagi, R. & Mattern, J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer 74, 64–68 (1997).
  Article CAS PubMed Google Scholar
• Yoshiji, H., Gomez, D. E., Shibuya, M. & Thorgeirsson, U. P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56, 2013–2016 (1996).
  CAS PubMed Google Scholar
• Ellis, L. M. et al. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer 34, 337–340 (1998).
  Article CAS PubMed Google Scholar
• Tomisawa, M. et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur. J. Cancer 35, 133–137 (1999).
  Article CAS PubMed Google Scholar
• Sowter, H. M. et al. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab. Invest. 77, 607–614 (1997).
  CAS PubMed Google Scholar
• Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843–845 (1992).
  Article CAS PubMed Google Scholar
• Plate, K. H., Breier, G., Weich, H. A. & Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845–848 (1992).
  Article CAS PubMed Google Scholar
• Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841–844 (1993). The earliest study to demonstrate that blocking VEGF suppresses angiogenesis and tumour growth in vivo.
  Article CAS PubMed Google Scholar
• Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A. & Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95, 1789–1797 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Melnyk, O., Shuman, M. A. & Kim, K. J. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res. 56, 921–924 (1996).
  CAS PubMed Google Scholar
• Borgstrom, P., Hillan, K. J., Sriramarao, P. & Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56, 4032–4039 (1996).
  CAS PubMed Google Scholar
• Borgstrom, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P. & Ferrara, N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35, 1–10 (1998).
  Article CAS PubMed Google Scholar
• Borgstrom, P., Gold, D. P., Hillan, K. J. & Ferrara, N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 19, 4203–4214 (1999).
  CAS PubMed Google Scholar
• Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576–579 (1994). This study demonstrated for the first time the key role of VEGFR2 signalling in tumour angiogenesis.
  Article CAS PubMed Google Scholar
• Strawn, L. M. et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540–3545 (1996).
  CAS PubMed Google Scholar
• Wood, J. M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178–2189 (2000).
  CAS PubMed Google Scholar
• Wedge, S. R. et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 60, 970–975 (2000).
  CAS PubMed Google Scholar
• Saleh, M., Stacker, S. A. & Wilks, A. F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56, 393–401 (1996).
  CAS PubMed Google Scholar
• Oku, T. et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 58, 4185–4192 (1998).
  CAS PubMed Google Scholar
• Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
  CAS PubMed Google Scholar
• Gerber, H. P., Kowalski, J., Sherman, D., Eberhard, D. A. & Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60, 6253–6258 (2000).
  CAS PubMed Google Scholar
• Kuo, C. J. et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl Acad. Sci. USA 98, 4605–4610 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393–11398 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715–725 (1998).
  Article CAS PubMed Google Scholar
• Tsuzuki, Y. et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α—> hypoxia response element—> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60, 6248–6252 (2000).
  CAS PubMed Google Scholar
• Inoue, M., Hager, J. H., Ferrara, N., Gerber, H. P. & Hanahan, D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β-cell carcinogenesis. Cancer Cell 1, 193–202 (2002). The first evidence that VEGF inhibition results in tumour suppression in a genetic model of cancer.
  Article CAS PubMed Google Scholar
• Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nature Rev. Cancer 3, 401–410 (2003).
  Article CAS PubMed Google Scholar
• Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15–R24 (2000). The study shows that VEGF blockade amplifies the effects of chemotherapy by blunting a key survival signal for endothelial cells.
  Article CAS PubMed PubMed Central Google Scholar
• Lee, C. G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
  CAS PubMed Google Scholar
• Kozin, S. V. et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
  CAS PubMed Google Scholar
• Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987–989 (2001).
  Article CAS PubMed Google Scholar
• Pham, C. D. et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 16, 225–230 (1998).
  Article CAS PubMed Google Scholar
• Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145–147 (2004). The study demonstrates that blocking VEGF has direct antivascular effects in colorectal cancer patients.
  Article CAS PubMed Google Scholar
• Presta, L. G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
  CAS PubMed Google Scholar
• Muller, Y. A. et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. Structure 6, 1153–1167 (1998).
  Article CAS PubMed Google Scholar
• Lin, Y. S. et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288, 371–378 (1999).
  CAS PubMed Google Scholar
• Davis-Smyth, T., Chen, H., Park, J., Presta, L. G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919–4927 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Fuh, G., Li, B., Crowley, C., Cunningham, B. & Wells, J. A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197–11204 (1998).
  Article CAS PubMed Google Scholar
• Kim, E. S. et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 99, 11399–11404 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Byrne, A. T. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9, 5721–5728 (2003).
  CAS PubMed Google Scholar
• Shima, D. T. et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest. Ophthalmol. Vis. Sci. 37, 1334–1340 (1996).
  CAS PubMed Google Scholar
• Margolin, K. et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19, 851–856 (2001).
  Article CAS PubMed Google Scholar
• Gordon, M. S. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843–850 (2001).
  Article CAS PubMed Google Scholar
• Reese, D. M. et al. A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J. 3, 65–70 (2001).
  Article Google Scholar
• Cobleigh, M. A. et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30, 117–124 (2003).
  Article CAS PubMed Google Scholar
• Yang, J. C. et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003). The first placebo-controlled study to show that blocking VEGF with bevacizumab has a clinical benefit in cancer patients.
  Article CAS PubMed PubMed Central Google Scholar
• Kabbinavar, F. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60–65 (2003).
  Article CAS PubMed Google Scholar
• DeVore, R. et al. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol. A1896 (2000).
• Saltz, L. B. et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6, 81–91 (2001).
  Article CAS PubMed Google Scholar
• Hurwitz, H. et al. A phase III randomized trial to evaluate the safety and efficacy of adding bevacizumab (rhuMAb VEGF) to bolus IFL in first line metastatic colorectal cancer. N. Engl. J. Med. (in the press). A key study that demonstrates that adding bevacizumab to chemotherapy confers a significant survival advantage to patients with previously untreated metastatic colorectal cancer.
• Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493–502 (2002).
  Article CAS Google Scholar
• Garber, K. Angiogenesis inhibitors suffer new setback. Nature Biotechnol. 20, 1067–1068 (2002).
  Article CAS Google Scholar
• Smith, J. K., Mamoon, N. M. & Duhe, R. J. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol. Res. 14, 175–225 (2004).
  Article PubMed Google Scholar
• Richly, H. et al. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 41, 620–621 (2003).
  Article CAS PubMed Google Scholar
• Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med. 9, 47–52 (2003).
  Article CAS PubMed Google Scholar
• Ruckman, J. et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556–20567 (1998).
  Article CAS PubMed Google Scholar
• Puliafito, C. The anti-VEGF aptamer approach: the macugen collaborative trial. Proc. Am. Acad. Ophthalmol. Subspecialty Day. The Retina Debates 2003: New Technology & Controversies from the Posterior Segment, Anaheim, California. 183–185 (2003).
• Chen, Y. et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865–881 (1999).
  Article CAS PubMed Google Scholar
• Goldberg, R. M. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23–30 (2004).
  Article CAS PubMed Google Scholar
• Miller, K. D. et al. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastine) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res. Treat. 76, S37 (2002).
  Article Google Scholar
• Kindler, L. et al. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer. Proc. Am Soc. Clin. Oncol. 22, 259 (2003).
  Google Scholar
• Carson, W. E. et al. A phase 2 trial of a recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma. Proc. Am. Soc. Clin. Oncol. A705 (2003).
• Herbst, R. S. et al. Phase I/II triall evaluating blockage of tumour blood supply and tumour cell proliferation with combines bevacizumab and erlotinib HCI as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur. J. Cancer 1, S293 (2003).
  Article Google Scholar
• Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727–739 (2002).
  Article CAS Google Scholar
• Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955–3964 (2003).
  Article CAS PubMed Google Scholar
• Gerber, H. P. & Ferrara, N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. 81, 20–31 (2003).
  Article CAS PubMed Google Scholar